Valiant Laboratories Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	1,334	1,821	3,339	3,124
Revenue Growth (YoY)	-26.74%	-45.48%	6.90%	-
Cost of Revenue	1,166	1,705	2,789	2,530
Gross Profit	167.82	115.76	549.82	594.07
Selling, General & Admin	43.88	43.13	46.13	33.44
Other Operating Expenses	170.74	156.71	152.79	101.43
Operating Expenses	235.54	219.49	214.55	159.13
Operating Income	-67.72	-103.73	335.28	434.94
Interest Expense	-1.75	-0.78	-2.54	-0.36
Interest & Investment Income	-	26.77	0.97	8.31
Currency Exchange Gain (Loss)	-	2.89	5.83	8.72
Other Non Operating Income (Expenses)	54.35	58.74	3.45	1.05
EBT Excluding Unusual Items	-15.13	-16.11	342.99	452.66
Gain (Loss) on Sale of Investments	-	8.42	38.37	-
Pretax Income	-15.13	-7.7	381.36	452.66
Income Tax Expense	6.89	-10.89	91.38	111.93
Net Income	-22.01	3.2	289.98	340.74
Net Income to Common	-22.01	3.2	289.98	340.74
Net Income Growth	-	-98.90%	-14.89%	-
Shares Outstanding (Basic)	43	38	33	33
Shares Outstanding (Diluted)	43	38	33	33
Shares Change (YoY)	13.57%	16.72%	-	-
EPS (Basic)	-0.51	0.08	8.91	10.46
EPS (Diluted)	-0.51	0.08	8.91	10.46
EPS Growth	-	-99.06%	-14.88%	-
Free Cash Flow	-1,125	-439.85	183.7	49.48
Free Cash Flow Per Share	-26.07	-11.57	5.64	1.52
Gross Margin	12.58%	6.36%	16.47%	19.02%
Operating Margin	-5.08%	-5.70%	10.04%	13.92%
Profit Margin	-1.65%	0.18%	8.68%	10.91%
Free Cash Flow Margin	-84.37%	-24.16%	5.50%	1.58%
EBITDA	-46.79	-85.98	349.23	456.55
EBITDA Margin	-3.51%	-4.72%	10.46%	14.62%
D&A For EBITDA	20.93	17.75	13.95	21.61
EBIT	-67.72	-103.73	335.28	434.94
EBIT Margin	-5.08%	-5.70%	10.04%	13.92%
Effective Tax Rate	-	-	23.96%	24.73%
Revenue as Reported	1,388	1,917	3,388	3,149

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.